Anthem Biosciences IPO fully subscribed on Day 2, led by NII, retail investors - Check latest GMP

Anthem Biosciences IPO fully subscribed on July 15.

Anthem Biosciences IPO got fully subscribed at 1.15 times on the second day of share sale on July 15. The initial share sale received bids for 5.08 crore shares against 4.40 crore shares on offer, according to NSE data, until 11 a.m.

Anthem Biosciences IPO subscription was led by the Non-institutional Investors category garnering 2.82 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 89 percent. The portion for Qualified Institutional Buyers (QIBs) received 38 percent subscription. The company raised Rs 1,016 crore from anchor investors.

The Rs 3,395-crore IPO of the Bengaluru-based firm will close on July 16. The price band has been fixed at Rs 540-570 per share.

According to websites tracking the grey market activities, the shares of Anthem Biosciences are commanding a GMP of around 20 percent in the unregulated market. Investorgain quoted a GMP of Rs 116 for the shares of the company, indicating a listing gain of 20.35 percent.

Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing.

It also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.

Shares of the company will be listed on both NSE and BSE on July 21, while the allotment is expected on July 17.